{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:59:35Z","timestamp":1789340375324,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T00:00:00Z","timestamp":1531353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00228-018-2499-0","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T09:10:00Z","timestamp":1531386600000},"page":"1405-1415","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin"],"prefix":"10.1007","volume":"74","author":[{"given":"Sabina","family":"Mugusi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliford","family":"Ngaimisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Janabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinand","family":"Mugusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omary","family":"Minzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Aris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Burhenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sandstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,12]]},"reference":[{"key":"2499_CR1","unstructured":"Tanzania HIV Impact Survery (THIS) 2016-2017. Available from \n                    http:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2017\/11\/Tanzania_SummarySheet_A4.English.v19.pdf"},{"key":"2499_CR2","unstructured":"National Tuberculosis and Leprosy program (NTLP) Tanzania, Treatment manual. Available from \n                    www.who.int\/hiv\/pub\/guidelines\/tanzania_tb.pdf"},{"key":"2499_CR3","unstructured":"National Policy guidelines for collaborative TB\/HIV activities. Available from \n                    http:\/\/www.nacp.go.tz\/site\/publications\/care-and-treatment"},{"key":"2499_CR4","unstructured":"Guidelines for the use of Antiretroviral agents in HIV-1 infected adults and adolescents. Available from \n                    https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf\n                    \n                  ."},{"key":"2499_CR5","unstructured":"Bristol-Myers Squibb Company: Product information, Sustiva (Efavirenz). Princeton, NJ. Available from \n                    https:\/\/packageinserts.bms.com\/pi\/pi_sustiva.pdf"},{"issue":"2","key":"2499_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1517\/14740338.6.2.147","volume":"6","author":"G Arendt","year":"2007","unstructured":"Arendt G, de Nocker D, von Giesen HJ, Nolting T (2007) Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 6(2):147\u2013154","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"2499_CR7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00042560-200108010-00003","volume":"27","author":"J Blanch","year":"2001","unstructured":"Blanch J, Mart\u00ednez E, Rousaud A, Blanco JL, Garc\u00eda-Viejo M\u00c1, Peri JM, Mallolas J, de Lazzari E, de Pablo J, Gatell JM (2001) Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 27(4):336\u2013343","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"2499_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1468-1293.2007.00533.x","volume":"9","author":"N Clumeck","year":"2008","unstructured":"Clumeck N, Pozniak A, Raffi F, the EACS Executive Committee (2008) European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 9(2):65\u201371","journal-title":"HIV Med"},{"key":"2499_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1471-2334-13-261","volume":"13","author":"JK Mukonzo","year":"2013","unstructured":"Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, Ogwal-Okeng J, Waako P, Gustafsson LL, Aklillu E (2013) Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis 13:261","journal-title":"BMC Infect Dis"},{"issue":"2","key":"2499_CR10","first-page":"103","volume":"11","author":"JA Munoz-Moreno","year":"2009","unstructured":"Munoz-Moreno JA et al (2009) Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev 11(2):103\u2013109","journal-title":"AIDS Rev"},{"issue":"4","key":"2499_CR11","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","volume":"3","author":"JA Perez-Molina","year":"2002","unstructured":"Perez-Molina JA (2002) Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 3(4):279\u2013286","journal-title":"HIV Clin Trials"},{"issue":"11","key":"2499_CR12","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1086\/497835","volume":"41","author":"F Gutierrez","year":"2005","unstructured":"Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, Martin-Hidalgo A (2005) Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41(11):1648\u20131653","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2499_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2165\/00023210-200216090-00002","volume":"16","author":"HE Wynn","year":"2002","unstructured":"Wynn HE, Brundage RC, Fletcher CV (2002) Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16(9):595\u2013609","journal-title":"CNS Drugs"},{"issue":"10","key":"2499_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2165\/00002018-200629100-00004","volume":"29","author":"MS Cespedes","year":"2006","unstructured":"Cespedes MS, Aberg JA (2006) Neuropsychiatric complications of antiretroviral therapy. Drug Saf 29(10):865\u2013874","journal-title":"Drug Saf"},{"issue":"8","key":"2499_CR15","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s10461-011-9939-5","volume":"15","author":"CA Kenedi","year":"2011","unstructured":"Kenedi CA, Goforth HW (2011) A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 15(8):1803\u20131818","journal-title":"AIDS Behav"},{"issue":"1","key":"2499_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1468-1293.2003.00136.x","volume":"4","author":"P Lochet","year":"2003","unstructured":"Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B, Reynes J (2003) Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med 4(1):62\u201366","journal-title":"HIV Med"},{"issue":"5","key":"2499_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1097\/01.qai.0000147523.41993.47","volume":"38","author":"CR Fumaz","year":"2005","unstructured":"Fumaz CR, Munoz-Moreno JA, Molt\u00f3 J, Negredo E, Ferrer MJ, Sirera G, P\u00e9rez-Alvarez N, G\u00f3mez G, Burger D, Clotet B (2005) Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 38(5):560\u2013565","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"2499_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","volume":"15","author":"C Marzolini","year":"2001","unstructured":"Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1):71\u201375","journal-title":"AIDS"},{"issue":"4","key":"2499_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00126334-200112010-00015","volume":"28","author":"M Nunez","year":"2001","unstructured":"Nunez M et al (2001) Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 28(4):399\u2013400","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"2499_CR20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1128\/AAC.48.3.979-984.2004","volume":"48","author":"RC Brundage","year":"2004","unstructured":"Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, Fletcher CV (2004) Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrob Agents Chemother 48(3):979\u2013984","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2499_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.103.049601","volume":"306","author":"BA Ward","year":"2003","unstructured":"Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306(1):287\u2013300","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"2499_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","volume":"81","author":"M Rotger","year":"2007","unstructured":"Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, D\u00e9costerd L, Blievernicht J, Saussele T, G\u00fcnthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81(4):557\u2013566","journal-title":"Clin Pharmacol Ther"},{"key":"2499_CR23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-6405-7-32","volume":"7","author":"V Gounden","year":"2010","unstructured":"Gounden V, van Niekerk C, Snyman T, George JA (2010) Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7:32","journal-title":"AIDS Res Ther"},{"issue":"7","key":"2499_CR24","doi-asserted-by":"publisher","first-page":"e40180","DOI":"10.1371\/journal.pone.0040180","volume":"7","author":"S Mugusi","year":"2012","unstructured":"Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, Riedel KD, Burhenne J, Lindquist L, Mugusi F, Sandstrom E, Aklillu E (2012) Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One 7(7):e40180","journal-title":"PLoS One"},{"issue":"3","key":"2499_CR25","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/clpt.2011.129","volume":"90","author":"E Ngaimisi","year":"2011","unstructured":"Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Bertilsson L, Burhenne J, Aklillu E (2011) Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. Clin Pharmacol Ther 90(3):406\u2013413","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2499_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/clpt.2010.172","volume":"88","author":"E Ngaimisi","year":"2010","unstructured":"Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E (2010) Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 88(5):676\u2013684","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2499_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1136\/jech.2008.081554","volume":"64","author":"B Lopman","year":"2010","unstructured":"Lopman B, Cook A, Smith J, Chawira G, Urassa M, Kumogola Y, Isingo R, Ihekweazu C, Ruwende J, Ndege M, Gregson S, Zaba B, Boerma T (2010) Verbal autopsy can consistently measure AIDS mortality: a validation study in Tanzania and Zimbabwe. J Epidemiol Community Health 64(4):330\u2013334","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"2499_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2471\/BLT.05.027003","volume":"84","author":"N Soleman","year":"2006","unstructured":"Soleman N, Chandramohan D, Shibuya K (2006) Verbal autopsy: current practices and challenges. Bull World Health Organ 84(3):239\u2013245","journal-title":"Bull World Health Organ"},{"key":"2499_CR29","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1.0. Available from \n                    http:\/\/rsc.tech-res.com\/Document\/safetyandpharmacovigilance\/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf"},{"issue":"4","key":"2499_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0005-7967(94)00082-U","volume":"33","author":"M Creamer","year":"1995","unstructured":"Creamer M, Foran J, Bell R (1995) The Beck anxiety inventory in a non-clinical sample. Behav Res Ther 33(4):477\u2013485","journal-title":"Behav Res Ther"},{"issue":"3","key":"2499_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0005-7967(94)00075-U","volume":"33","author":"PF Lovibond","year":"1995","unstructured":"Lovibond PF, Lovibond SH (1995) The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the Beck depression and anxiety inventories. Behav Res Ther 33(3):335\u2013343","journal-title":"Behav Res Ther"},{"issue":"11","key":"2499_CR32","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00228-011-1065-9","volume":"67","author":"E Aklillu","year":"2011","unstructured":"Aklillu E, Mugusi S, Ngaimisi E, Hoffmann MM, K\u00f6nig S, Ziesenitz V, Mikus G, Haefeli WE, Weiss J (2011) Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler(R)-based method. Eur J Clin Pharmacol 67(11):1139\u20131145","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"2499_CR33","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/jac\/dkr304","volume":"66","author":"A Habtewold","year":"2011","unstructured":"Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N, Worku A, Haefeli WE, Lindquist L, Aderaye G, Burhenne J, Aklillu E (2011) Long-term effect of efavirenz autoinduction on plasma\/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 66(10):2350\u20132361","journal-title":"J Antimicrob Chemother"},{"issue":"16","key":"2499_CR34","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1097\/QAD.0b013e32832e95f8","volume":"23","author":"TR Read","year":"2009","unstructured":"Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, Wand H, Emery S (2009) Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS 23(16):2222\u20132223","journal-title":"AIDS"},{"issue":"2","key":"2499_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00003088-200746020-00002","volume":"46","author":"K Dahri","year":"2007","unstructured":"Dahri K, Ensom MH (2007) Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? Clin Pharmacokinet 46(2):109\u2013132","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2499_CR36","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/jac\/dkl357","volume":"58","author":"LF Lopez-Cortes","year":"2006","unstructured":"Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R (2006) Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 58(5):1017\u20131023","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"2499_CR37","doi-asserted-by":"publisher","first-page":"e67946","DOI":"10.1371\/journal.pone.0067946","volume":"8","author":"E Ngaimisi","year":"2013","unstructured":"Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J (2013) Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations. PLoS One 8(7):e67946","journal-title":"PLoS One"},{"issue":"10","key":"2499_CR38","doi-asserted-by":"publisher","first-page":"714","DOI":"10.7326\/0003-4819-143-10-200511150-00008","volume":"143","author":"DB Clifford","year":"2005","unstructured":"Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM, for the A5097s Study Team* (2005) Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 143(10):714\u2013721","journal-title":"Ann Intern Med"},{"issue":"2","key":"2499_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","volume":"61","author":"D Burger","year":"2006","unstructured":"Burger D, van der Heiden I, la Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, Schenk P, van Schaik R (2006) Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 61(2):148\u2013154","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"2499_CR40","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/aid.2006.0193","volume":"23","author":"M Takahashi","year":"2007","unstructured":"Takahashi M, Ibe S, Kudaka Y, Okumura N, Hirano A, Suzuki T, Mamiya N, Hamaguchi M, Kaneda T (2007) No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. AIDS Res Hum Retrovir 23(8):983\u2013987","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"2499_CR41","first-page":"3","volume":"17","author":"RK Heaton","year":"2011","unstructured":"Heaton RK et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neuro-Oncol 17(1):3\u201316","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"2499_CR42","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","volume":"56","author":"JC Adkins","year":"1998","unstructured":"Adkins JC, Noble S (1998) Efavirenz. Drugs 56(6):1055\u20131064 discussion 1065-6","journal-title":"Drugs"},{"issue":"3","key":"2499_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/0956462413498581","volume":"25","author":"SS Lee","year":"2014","unstructured":"Lee SS, To KW, Lee MP, Wong NS, Chan DPC, Li PCK, Cheung SW, Chan RCY (2014) Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G\/T polymorphisms. Int J STD AIDS 25(3):193\u2013200","journal-title":"Int J STD AIDS"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2499-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2499-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2499-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T23:55:13Z","timestamp":1562889313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2499-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,12]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["2499"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2499-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,12]]},"assertion":[{"value":"3 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}